4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its third-quarter update after the market close on Monday.
What are investors' specific concerns? How serious are those concerns? Here are four reasons some might worry about Vertex -- and how those reasons are easily debunked.
The obvious reason to worry after Vertex's Q3 update is that the company missed Wall Street's revenue estimate. There were quite a few articles published Monday evening and Tuesday highlighting this fact. But it's important to keep four things in mind.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
432,65 €
0,38 %
Die Aktie ist durchaus ein Favorit unsere Community mit 57 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Ein leichtes Potenzial nach oben für Vertex Pharmaceuticals Inc. mit einem Kursziel von 440 € gegenüber dem aktuellen Kurs von 432.65 €.
